We believe that the next step would be its validation in prospective clinical trials evaluating specific applications, such as molecular residual disease in patients with advanced disease who have presented a prolonged CR, where the discontinuation of treatment with both ICI and BRAF/MEKi is considered, or the adaptation of treatment in advanced settings based on ctDNA evolution, such as the currently ongoing CacTUS phase II trial, which aims to switch treatment based on ctDNA response in BRAFV600-mutant melanoma patients. This evidence concerns the gene BRAF and melanoma.